Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Vera Therapeutics Inc VERA

Healthcare Biotechnology
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self... see more

Current News (NDAQ:VERA)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5 days ago

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 6 days ago

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

GlobeNewswire 7 days ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

GlobeNewswire December 9, 2025

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

GlobeNewswire December 8, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2025

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

GlobeNewswire November 26, 2025

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire November 24, 2025

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

GlobeNewswire November 10, 2025
View More News ››

Opinion & Analysis (NDAQ:VERA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VERA)

Vera Therapeutics, Inc. (NASDAQ:VERA): A Late-Stage Biotech

http://beyondspx.com/2024/08/01/vera-therapeutics-inc-nasdaqvera-a-late-stage-biotech-poised-for-transformative-growth/
MikeTester - August 2, 2024
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts